4-cyclopropyl-1,2-dimethoxybenzene | 83356-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-cyclopropyl-1,2-dimethoxybenzene
• 英文别名: 3,4-dimethoxyphenylcyclopropane；4-cyclopropyl-1,2-dimethoxy-benzene
• CAS: 83356-71-2
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: RWKOXGSVFPOELN-UHFFFAOYSA-N

物化性质

• 沸点：
  155-156 °C(Press: 19 Torr)
• 密度：
  1.077±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-cyclopropyl-1,2-dimethoxybenzene 在 dinitrogen tetraoxide 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以92%的产率得到4,5-dimethoxy-2-nitrophenylcyclopropane
  参考文献：
  名称：

  与四氧化二氮反应的环丙基和烯丙基取代的芳烃。底物氧化电位对反应方向的影响

  摘要：

  A correlation was found between oxidation potentials of acylcyclopropanes in solution (in CH2Cl2 and CH3CN) and their HOMO energies calculated by semiempirical (AM1) and nonempirical (HF/6-31G and HF/6-31G**) methods. The correlation provides a possibility to forecast the reaction direction of the mentioned substrates and N2O4. The correlation possesses a general character. It was established for instance that arylcyclopropanes, cyclopropylmethyl- and allylbenzenes oxidized at more positive potentials than reduction potential of NO+ and having more positive epsilon(HOMO) than -9.0 eV (AM1), -8.4 eV (HF/6-31G), and -8.3 eV (HF/6-31 G**) reacted with N2O4 following the mechanism "electron transfer - radical pair recombination" affording nitroaromatic derivatives retaining the cyclopropane (or allyl) fragments. Substrates of the same type where the electron transfer to NO+ should be endothermic process and whose HOMO values are less than the above critical numbers react with N2O4 by the mechanism of electrophilic cyclopropane ring opening (with aryl and benzylcyclopropanes) or by electrophilic addition across the double C=C bond (with allylbenzenes).

  DOI：

  10.1023/b:rujo.0000045888.43245.d7
• 作为产物：
  描述：

  1-(3,4-二甲氧基苯基)-1-丙酮 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 4-cyclopropyl-1,2-dimethoxybenzene
  参考文献：
  名称：

  Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

  摘要：

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸系统和胃肠道疾病的方法，包括向有此需要的受试者施用有效量的式(I)化合物：或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。

  公开号：

  US20070049609A1

文献信息

• Reductive Cyclopropanations Catalyzed by Dinuclear Nickel Complexes
  作者：You-Yun Zhou、Christopher Uyeda

  DOI：10.1002/anie.201511271

  日期：2016.2.24

  Dinuclear Ni complexes supported by naphthyridine‐diimine (NDI) ligands catalyze the reductive cyclopropanation of alkenes with CH2Cl2 as the methylene source. The use of mild terminal reductants (Zn or Et2Zn) confers significant functional‐group tolerance, and the catalyst accommodates structurally and electronically diverse alkenes. Mononickel catalysts bearing related N chelates afford comparatively

  萘啶二亚胺（NDI）配体支持的双核Ni络合物以CH 2 Cl 2为亚甲基源催化烯烃的还原环丙烷化。使用温和的末端还原剂（Zn或Et 2 Zn）可赋予显着的官能团耐受性，并且该催化剂可容纳结构和电子形式多样的烯烃。带有相关N螯合物的单镍催化剂提供相对较低的环丙烷收率（≤20％）。这些结果构成了从氧化的亚甲基前体进入催化卡宾转化的进入。
• Diaminopyrimidines as P2X3 and P2X2/3 antagonists
  申请人：Broka Allen Chris

  公开号：US20050209260A1

  公开（公告）日：2005-09-22

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法，该方法包括向有需要的受试者施用有效量的式I化合物：或其药学上可接受的盐、溶剂化物或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• Cooperative NHC/Photoredox Catalyzed Ring‐Opening of Aryl Cyclopropanes to 1‐Aroyloxylated‐3‐Acylated Alkanes
  作者：Zhijun Zuo、Constantin G. Daniliuc、Armido Studer

  DOI：10.1002/anie.202110304

  日期：2021.11.22

  Ring-opening/arylcarboxylation/acylation of mono, di and trisubstituted cyclopropanes enabled by cooperative NHC and organophotoredox catalysis for the preparation of γ-aroyloxy ketones is reported. Key step is the radical/radical cross- coupling of a benzylic radical generated in the photoredox catalysis cycle and a ketyl radical formed in the NHC catalysis cycle.

  报道了通过 NHC 和有机光氧化还原协同催化实现单、二和三取代环丙烷的开环/芳基羧化/酰化，用于制备 γ-芳酰氧基酮。关键步骤是光氧化还原催化循环中产生的苄基自由基和NHC催化循环中形成的羰基自由基的自由基/自由基交叉偶联。
• [EN] DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS<br/>[FR] DIAMINOPYRIMIDINES UTILISEES EN TANT QU'ANTAGONISTES DE P2X3 ET P2X2/3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005095359A1

  公开（公告）日：2005-10-13

  Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonists, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

  本发明涉及用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的化合物和方法，所述方法包括向需要治疗的受体中给予公式（I）的化合物或其药学上可接受的盐、溶剂或前药的有效量，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Broka Chris Allen

  公开号：US20110077242A1

  公开（公告）日：2011-03-31

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  本发明涉及化合物和方法，用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病，其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量，或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。